Toft Group Completes Executive Search for Natera, Inc. (NASDAQ:NTRA) in San Carlos, CA

natera logo

Executive search firm Toft Group has placed Michael C. Little, Ph.D. as Senior Vice President, R&D at Natera, Inc. (NASDAQ: NTRA). Prior to Natera, Dr. Little was the Global Head of Diagnostics Development at Novartis. During his tenure, Dr. Little managed the diagnostic development of all molecular diagnostic programs, as well as oncology and general medicine companion diagnostic programs. Previously, Dr. Little served as Vice President, R&D, Medical Affairs, Regulatory & Scientific Affairs, and Program Management at Novartis Diagnostics.

Dr. Little holds a Ph.D. in Microbiology, and has over 27 years' experience in biotech and diagnostics research and commercialization. His organizations have comprised chemistry, engineering, bioinformatics, pathology, kit manufacturing, program management functions, quality control and regulatory affairs.

"We are delighted to welcome Mike to Natera where he will leverage his deep experience managing large numbers of complex diagnostics projects," said Matthew Rabinowitz, Ph.D., CEO of Natera. "Mike will lead our R&D team's product development efforts and strategic planning, particularly as it relates to the evolving regulatory landscape."

Robin Toft, President and CEO of Toft Group said: “We are thrilled to have worked with the senior leadership of Natera to select Dr. Little, and congratulate him on his new role. We have every confidence that he will make an exceptional contribution to the company’s continued growth and success.”

About Toft Group

Toft Group Executive Search is a global retained executive search firm that is 100% dedicated to Life Sciences & Healthcare industries, including biotech, pharmaceutical, medical device and diagnostic companies. With offices in San Francisco, San Diego and Boston, our client list spans a wide range of local, national and international companies - from venture backed start-ups to Fortune 500 corporations. Our mission is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market.

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.